How to Write ABPI-Compliant Social Media Copy for Pharma

Social media has become one of the most scrutinised channels in pharmaceutical marketing. The ABPI Code of Practice 2021 does not carve out a separate rulebook for LinkedIn, X, or Instagram — every post, comment, and reshare is held to the same standards as a printed detail aid. This guide walks through what that means in practice, and how to write social copy that clears MLR review the first time.

What the ABPI Code of Practice Covers on Social Media

The ABPI Code of Practice is the self-regulatory framework governing the promotion of prescription medicines to UK healthcare professionals and communication with the public. Clause 5 (high standards), Clause 6 (accuracy and balance) and Clause 26 (public-facing communications) apply to social media in full.

The 2021 update clarified three points that catch teams out most often: promotional content for prescription-only medicines cannot be directed to the public, disease-awareness posts must not identify a specific product, and every claim — including in image captions and alt text — must be capable of substantiation.

Fair Balance in a 280-Character World

Fair balance means safety information must be presented with the same prominence as efficacy claims. On social this is harder than on a landing page, but it is not optional.

Practical patterns that hold up under review:

• Never make an efficacy claim without adjacent safety information in the same post — not a linked thread, not a reply.
• If character limits force a trade-off, drop the claim, not the safety information.
• Link to the full prescribing information from every promotional post directed to healthcare professionals.
• Treat images and video captions as copy — they carry the same obligations as body text.

Audience Targeting: HCP vs Public

The Code draws a hard line between healthcare professionals and the public. Prescription-only medicine promotion is permitted to the first group and prohibited to the second.

On social media, audience is defined by who can see the post, not who you intended to reach. That has practical consequences:

• Open accounts on X, Instagram, TikTok and Facebook are treated as public-facing. Do not promote prescription medicines on them.
• LinkedIn is public unless you use gated groups or targeted advertising with HCP verification.
• Boosted or paid posts inherit the audience of the targeting — if the targeting is not HCP-verified, the post is public.
• Reshares by employees or KOLs count as your communication. Brief them and log approvals.

Disease Awareness Without Product Promotion

Public-facing disease awareness is allowed and encouraged, but it must not identify a specific medicine. That includes indirect identification through images, hashtags, or account handles that map one-to-one to a product.

Safe patterns: talk about the condition, symptoms, and when to seek advice. Avoid patterns: naming molecule or brand, showing pack shots, or linking to product pages from the same post.

Channel-Specific Pitfalls

Each platform has quirks that create Code risk if you do not plan for them:

• LinkedIn: employee reshares of promotional posts extend your audience beyond HCPs — assume public reach unless controls exist.
• X: threads can separate a claim from its safety information. Keep both in the first post.
• Instagram and TikTok: captions are truncated in-feed. Put safety information before the fold, not after 'more'.
• Comments and DMs: replies from your brand account are promotional communication. Do not respond to individual patient questions about therapy.

A Review-Ready Checklist

Before a social post enters MLR, run it through this list:

• Is the audience clearly HCP or public, and does the content match?
• Is every efficacy claim accompanied by safety information in the same post?
• Is every claim substantiated by a referenced source?
• Are images, captions, hashtags and alt text held to the same standard as body copy?
• Is the adverse event reporting statement present where required?
• Have reshares, boosts, and employee amplification been approved as part of the same review?

How RegScribe Helps

RegScribe generates first-draft social copy that starts from the ABPI Code rather than retrofitting compliance at the end. Every variation includes fair-balance framing, a safety disclaimer, and a reference block — so your MLR team spends time refining nuance, not rewriting structure.

It is a drafting aid, not a substitute for review. But starting from a compliant template turns social from your riskiest channel into one of your fastest.